Advanced Bifurcation Systems

About Advanced Bifurcation Systems

Advanced Bifurcation Systems operates in the medical device industry, focusing on innovative solutions for coronary artery disease, specifically at bifurcation points where arteries branch. The company's core product is a bifurcation stent designed to evenly scaffold all bifurcations regardless of angles, sizes, or plaque location, simplifying the procedure for interventional cardiologists. The technology is protected by more than 36 issued and 12 pending patents, positioning it as a disruptive force in the $2.5 billion global bifurcations market.

The company primarily serves healthcare providers, including hospitals and specialized cardiology clinics, aiming to improve outcomes for millions of patients worldwide who face either Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG). Advanced Bifurcation Systems operates on a B2B business model, generating revenue through the sale of its patented stenting systems and related medical devices.

The company has submitted a proposal to the U.S. Federal Drug Administration (FDA) for a clinical study leading to an Investigational Device Exemption (IDE) for its bifurcation technology. This regulatory milestone is crucial for market penetration and widespread adoption.

Key members of the leadership team include Henry Bourang, President and COO, with over 30 years of experience in the medical device industry, and Richard Ferrari, Director, who brings extensive expertise in endovascular interventions. The company's scientific advisory board comprises leading interventional cardiologists and experts in the field.